Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Cystic Fibrosis Foundation honors Greenberg Traurig attorney D. Porpoise Evans

D. Porpoise Evans, a litigation associate in the Miami office of the international law firm Greenberg Traurig P.A., has been named among the "40 Under 40" outstanding lawyers of Miami-Dade County by the Cystic Fibrosis Foundation (CFF). The 40 lawyers will be honored at the CFF benefit dinner on November 20, 2009 at the Intercontinental Hotel in Miami.

14 Oct 2009

University of North Carolina awarded grant to continue research on rare disease-causing gene mutations

The University of North Carolina at Chapel Hill has been awarded a five-year, $6.2 million renewal grant to continue its work as part of the National Institutes of Health's Rare Diseases Clinical Research Network (RDCRN).

14 Oct 2009

Older generation antibiotic for treating colon cancer

A new Tel Aviv University drug, based on an older generation antibiotic, may provide doctors with an effective and innovative method of treating colon cancer in both its incipient and full-blown stages ― and minimize the need for painful, uncomfortable colonoscopies and surgical polyp removal.

14 Oct 2009

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

NanoBio Corporation today announced an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with “Innate Immune Receptors and Adjuvant Discovery.” NanoBio is the principal subcontractor for the $9.3 million contract awarded to the University of Michigan.

14 Oct 2009

Wake Forest University School of Medicine honours researchers

Wake Forest University School of Medicine honored eight of its researchers with awards for excellence at the 13th Annual Research Awards Day Oct. 1.

12 Oct 2009

Riley Hospital for Children commences patient enrollment in clinical trial of cystic fibrosis drug

The Riley Hospital for Children Cystic Fibrosis Center is the first site in the nation to enroll patients ages 6-11 for the first part of a 48-week clinical trial of a promising investigational treatment for cystic fibrosis (CF).

9 Oct 2009

CREON Delayed-Release Capsules improves fat absorption in patients with Cystic Fibrosis

Solvay Pharmaceuticals, Inc. announced that Phase III data published in the Journal of Cystic Fibrosis showed that CREON® (pancrelipase) Delayed-Release Capsules, the most prescribed pancreatic enzyme replacement therapy (PERT) in the United States, significantly improves a key measure of fat absorption in patients with CF who suffer from exocrine pancreatic insufficiency (EPI).

9 Oct 2009

HDSA honors outstanding contributors against Huntington's Disease

The Huntington's Disease Society of America (HDSA), will recognize the outstanding contributions to improving the quality of life of people with Huntington's Disease (HD) by several individuals and two organizations at the 13th annual Guthrie Awards Dinner this Thursday.

7 Oct 2009

Research to explore diagnosis and treatment of rare diseases

The National Institutes of Health announced today a second phase of the Rare Diseases Clinical Research Network (RDCRN) including funds for 19 research consortia.

7 Oct 2009

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.

5 Oct 2009

Vertex Pharmaceuticals to receive $155 million in cash from two financial transactions

Vertex Pharmaceuticals Incorporated today announced that it will receive $155 million in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 million in cash for the issuance of notes repayable no later than October 31, 2012 in the total amount of $155 million.

1 Oct 2009

NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of small molecules to alleviate multiple chronic human diseases including cystic fibrosis (CF), hypertension and chronic kidney diseases with hypertension.

28 Sep 2009

European Commission grants conditional marketing authorization for Gilead's Cayston

Gilead Sciences, Inc. announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF) aged 18 years and older.

28 Sep 2009

Vertex Pharmaceuticals to present SVR data at the 60th Annual Meeting of the American Association

Vertex Pharmaceuticals Incorporated today announced that sustained virologic response (SVR) data from Study C208, which evaluated twice-daily dosing of Vertex’s investigational hepatitis C virus (HCV) protease inhibitor telaprevir, will be presented in an oral presidential plenary session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place Oct. 30 – Nov. 3, 2009 in Boston.

25 Sep 2009

NIH Director's Pioneer Award and New Innovator Award for Duke scientists

Two Duke University Medical Center scientists have won prestigious National Institutes of Health Director's awards to pursue novel research.

24 Sep 2009

A 2,000-mile scooter journey to raise cystic fibrosis awareness

Emily Schaller, a 27-year-old drummer with cystic fibrosis (CF), begins a 2,000-mile journey today aboard a Vespa scooter -- riding from Chicago to Burbank, California, in her quest to get on "The Ellen DeGeneres Show."

22 Sep 2009

Employees of Vertex Pharmaceuticals take part in volunteer activities

Vertex Pharmaceuticals Incorporated today announced that approximately 800 employees took part in Vertex’s first companywide Day of Service, which was held on Friday, September 18, 2009.

22 Sep 2009

Live webcast of Vertex's presentations at UBS Global Life Sciences Conference

Vertex Pharmaceuticals Incorporated today announced that it will webcast its presentations at the UBS Global Life Sciences Conference on Tuesday, September 22, 2009 at 2:30 p.m. EDT and at the JMP Securities Healthcare Conference on Monday, October 5, 2009 at 10:00 a.m. EDT.

19 Sep 2009

'Pathway to a Cure' walk event in California

Satellite Healthcare, one of the nation's first and leading providers of kidney dialysis services and a major sponsor of nephrology research, today announced their sponsorship of The Polycystic Kidney Disease Foundation's "Pathway to a Cure" walk event in California's capital of Sacramento.

18 Sep 2009

SEQUENOM's first laboratory developed cystic fibrosis test launched

SEQUENOM, Inc. today announced that the company's first laboratory developed test, the SensiGene(TM) Cystic Fibrosis (CF) Carrier Screening test, has been launched.

18 Sep 2009

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Cystic Fibrosis Foundation honors Greenberg Traurig attorney D. Porpoise Evans

University of North Carolina awarded grant to continue research on rare disease-causing gene mutations

Older generation antibiotic for treating colon cancer

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

Wake Forest University School of Medicine honours researchers

Riley Hospital for Children commences patient enrollment in clinical trial of cystic fibrosis drug

CREON Delayed-Release Capsules improves fat absorption in patients with Cystic Fibrosis

HDSA honors outstanding contributors against Huntington's Disease

Research to explore diagnosis and treatment of rare diseases

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Vertex Pharmaceuticals to receive $155 million in cash from two financial transactions

NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis

European Commission grants conditional marketing authorization for Gilead's Cayston

Vertex Pharmaceuticals to present SVR data at the 60th Annual Meeting of the American Association

NIH Director's Pioneer Award and New Innovator Award for Duke scientists

A 2,000-mile scooter journey to raise cystic fibrosis awareness

Employees of Vertex Pharmaceuticals take part in volunteer activities

Live webcast of Vertex's presentations at UBS Global Life Sciences Conference

'Pathway to a Cure' walk event in California

SEQUENOM's first laboratory developed cystic fibrosis test launched

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in